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We were aware of both these papers during our study, but we failed
to refer to them as they represent different patient populations to
our own. However, we agree that, as we did not present data on the
diurnal variation in soluble P-selectin and soluble thrombomodu-
lin in healthy subjects, we were perhaps premature to interpret this
data in terms of “loss” of a pattern in the patients with AF,
although this lack of diurnal variation is in keeping with our
hypothesis of a “constant” hypercoagulable state in AF.
Naturally, there are many confounders to be addressed in studies
of thrombosis and hemostasis, and ours is typical in that athero-
sclerosis and its risk factors were present in some of our patients
with AF. It has previously been shown that the hypercoagulable
state in AF is independent of underlying etiology or associated
heart disease (9), and we would emphasize that the main objective
of our study was to assess the circadian or diurnal variation in the
hypercoagulable state in AF, rather than to reproduce many
previous analyses (including our own) of the effects of heart disease
on hypercoagulability in AF. Indeed, we were unable to find any
difference in our research indices comparing those patients with
lone AF with those whose AF was confounded by other disease
(1). Despite this, our cohort of patients are indeed characteristic of
those presenting to the hospital with AF, and so the data are truly
representative of a “real-life” situation.
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C-Reactive Protein and Electron Beam
Computed Tomography: A Perfect Match?
Redberg et al. (1) are incorrect in concluding that electron beam
computed tomography (EBCT) may not predict future coronary
events because there is no evidence of a positive association
between C-reactive protein and coronary calcium. The presence of
atherosclerosis (EBCT calcium) and inflammation (C-reactive
protein) are both predictors of future events. This study adequately
demonstrated that the two are not dependent upon one another.
Published data from the Cholesterol And Recurrent Events
(CARE) trial demonstrated that many patients with established
coronary disease (myocardial infarction [MI]) had normal or low
C-reactive protein levels (2). The significant finding in the
Cholesterol And Recurrent Events (CARE) study is that coronary
disease plus inflammation (C-reactive protein) predicted future
events. However, it is incorrect to assume that a low C-reactive
protein in the setting of MI is protective. These patients are still at
greatly increased risk over non-MI persons. Lack of association of
C-reactive protein with EBCT does not imply that EBCT, nor
C-reactive protein, will fail to predict cardiac events.
The investigators made a series of small errors with the EBCT
literature that deserve comment. They quote a fluoroscopy study
stating “that individuals with normal EBCT scores may nonethe-
less suffer MI.” EBCT is significantly more sensitive than flouro-
scopy for detection of coronary disease and prediction of future
cardiac events. They also state that calcium score is a weak
predictor of coronary death and infarction. A recent meta-analysis
of EBCT demonstrated there was an increased risk for hard events:
MI or death (summary risk ratio 4.2 using median calcium scores)
(3). When studies evaluate the highest quartile of calcium score as
compared with the lowest quartile, odds ratios (ORs) are on the
order of 10 to 20 (4–6). Thus, EBCT is potentially as robust a
predictor of future cardiac events as C-reactive protein (OR of 4.4
using quartile analysis) (7).
The question answered in the paper is that not every asymp-
tomatic person with atherosclerosis has inflammation, which was
known from the CARE study. Atherosclerosis predicts future
cardiac events, inflammation predicts future events, and the com-
bination more strongly predicts future events (2). The detection of
atherosclerosis (calcium by EBCT) and inflammation (C-reactive
protein) might predict future events robustly, and this is actively
being investigated.
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REPLY
We appreciate Dr. Budoff’s interest in our paper on C-reactive
protein and calcium in postmenopausal women. The hypothesis
tested in our study (1) was whether postmenopausal women
enrolled in the Females, Lipids, Activity and Sex Hormones
(FLASH) study with coronary calcium by electron beam computed
tomography (EBCT) would have higher concentrations of high
sensitivity testing for C-reactive protein (hsCRP), an inflamma-
tory marker believed to be an independent risk factor for cardio-
vascular disease (2). However, we found no evidence of a positive
association of hsCRP and calcium by EBCT. We suggested that
hsCRP may be a marker for inflammation and EBCT may be a
marker for mature and more stable atherosclerotic plaque. We also
stated that these data highlight the importance of careful prospec-
tive clinical evaluation of emerging technologies such as EBCT,
the same conclusion reached by the recent American College of
Cardiology/American Heart Association (ACC/AHA) Expert
Consensus panel on EBCT (3).
Dr. Budoff takes issue with our statement that “individuals with
normal EBCT scores may nonetheless suffer MI.” However, this
statement is supported by the data not only in the paper referenced,
but also in papers by Secci (4) (ref. 27 in the paper), Arad (5) (ref.
14 in the paper), South Bay Heart Watch (6) (ref. 28 in the paper),
Raggi (7), and by the recent ACC/AHA statement (3).
In addition, Dr. Budoff states that “the question answered in the
paper is that not every asymptomatic person with atherosclerosis
has inflammation, which was known from the CARE study.”
However, as the CARE study exclusively studied patients after
myocardial infarction, it did not provide any information about
asymptomatic persons. Similarly, the FLASH study patients were
all asymptomatic, but many did not have atherosclerosis. Thus, his
interpretation of these papers is inconsistent with their study
designs.
Finally, the CARE study did not measure EBCT scores. Hence,
Dr. Budoff’s statement that the CARE study (8) showed that the
“combination [calcium scores and hsCRP levels] more strongly
predicts future events” is incorrect. However, we agree with Dr.
Budoff that this is an important hypothesis to test.
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